Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2026 14:34 ET | Source: Robbins LLP

Robbins LLP Urges ATRA Stockholders to Contact the Firm for Information About the Class Action Against Atara Biotherapeutics, Inc.

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
April 21, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
March 31, 2026 20:51 ET | Source: Robbins LLP

Did You Lose Money Investing in Atara Biotherapeutics, Inc.? Robbins LLP Encourages Investors with Significant Losses to Contact the Firm About Their Rights Against ATRA

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
March 27, 2026 14:23 ET | Source: Robbins LLP

IBRX Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against ImmunityBio, Inc.

Robbins LLP is Investigating Allegations that ImuunityBio, Inc. (IBRX) Misled Investors Regarding its Lead Product Candidate
March 26, 2026 17:28 ET | Source: Robbins LLP

ATRA Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Atara Biotherapeutics, Inc. Class Action

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
February 20, 2026 17:11 ET | Source: Robbins LLP

RGNX Stockholder Alert: Robbins LLP Remind Investors of the Class Action Lawsuit Against REGENXBIO, Inc.

Robbins LLP is Investigating Allegations that REGENXBIO, Inc. (RGNX) Misled Investors Regarding the Viability of its Drug Candidate RGX-111
February 16, 2026 19:42 ET | Source: Robbins LLP

QURE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the uniQure N.V. Class Action

The Allegations: Robbins LLP is Investigating Allegations that uniQure (QURE) Misled Investors Regarding the Likelihood of FDA Approval of its Drug.
November 28, 2025 02:30 ET | Source: INVENTIVA

Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 27 novembre 2025

Daix (France), New York City (New York, Etats-Unis), le 28 novembre 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le...
November 28, 2025 02:30 ET | Source: INVENTIVA

Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025

Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...
November 25, 2025 15:31 ET | Source: Robbins LLP

MLTX Class Action Reminder – Robbins LLP Reminds MoonLake Immunotherapeutics Stockholders of the Opportunity to Lead the Class Action Lawsuit

Robbins LLP alerts investors to a class action involving MoonLake, alleging misleading statements on a drug candidate’s efficacy.